drugset
drugset / Trial / NCT04227015

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

NCT04227015 ↗

Phase 0 Recruiting 72 enrolled He Huang Nanjing Bioheng Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

Timeline

Start
2020-01-08
Primary completion
2022-01-08
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CTA101 Cell therapy — Intravenous

Indications

acute lymphoblastic leukemia